Every material Form 8-K Neuronetics, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neuronetics reported third-quarter 2026 total revenue of $42.0 million, up 12.5% from a year earlier, with the Greenbrook clinic network driving most of the growth. The net loss attributable to stockholders narrowed to $1.7 million, or $0.02 per share, from $9.0 million, or $0.13 per share, and the company raised the low end of its full-year gross margin outlook while lowering its operating expense forecast.
Q3 2026 total revenue was $42.0 million, up 12.5%; Greenbrook revenue rose 20.1% to $26.2 million.
Net loss attributable to stockholders was $1.7 million, or $0.02 per share, versus $9.0 million, or $0.13 per share, in Q3 2025.
Full-year 2026 revenue guidance is unchanged at $160 million to $164 million; gross margin guidance is now 49% to 50%, up from 48% to 50%.
Full-year 2026 operating expense guidance was lowered to $92.5 million to $95.5 million from $95 million to $100 million.
Neuronetics said Nir Naor, its Executive Vice President and Chief Financial Officer, was appointed principal financial and accounting officer on August 12, 2026, ending Francis X. Brown III's interim role effective August 11, 2026. Brown will continue as a consultant, and the filing states no disagreement with the company led to the change.
Nir Naor appointed principal financial and accounting officer by the Board on August 12, 2026
Naor's title is now Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer
Francis X. Brown III's interim role ended August 11, 2026; he will continue as a consultant
Naor received no new compensation for the appointment or title change
Neuronetics reported second-quarter 2026 revenue of $41.6 million, up 9.1% from a year earlier, driven by Greenbrook clinic revenue. Net loss narrowed to $3.4 million from $10.1 million, but the company trimmed the top end of its full-year 2026 revenue guidance and appointed a new chief financial officer.
Total revenue $41.6 million, up 9.1%; Greenbrook revenue $26.9 million, up 16.8%
Net loss $3.4 million, or $0.05 per share, versus $10.1 million, or $0.15 per share, a year earlier
FY2026 revenue guidance $160 million to $164 million, versus prior $160 million to $166 million
Nir Naor appointed Executive Vice President and Chief Financial Officer
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neuronetics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →